DiaMedica Therapeutics (DMAC) Profit After Tax (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Profit After Tax for 9 consecutive years, with -$10.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 31.51% year-over-year to -$10.2 million; the trailing twelve-month figure through Jun 2026 stood at -$37.6 million (down 26.98% YoY), and the FY2025 full-year result was -$32.8 million, down 34.18% from the prior year.
• Profit After Tax retreated to -$10.2 million in Q2 2026 per DMAC's latest filing, from -$10.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$3.1 million in Q3 2022 and bottomed at -$10.2 million in Q2 2026.
• Historically, Profit After Tax has averaged -$6.1 million across 5 years, with a median of -$5.2 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax advanced 11.38% in 2022, then sank 54.66% in 2024.
• Over 5 years, Profit After Tax stood at -$3.7 million in 2022, then tumbled by 39.45% to -$5.1 million in 2023, then plunged by 54.66% to -$7.9 million in 2024, then dropped by 11.06% to -$8.8 million in 2025, then decreased by 15.68% to -$10.2 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$10.2 million, -$10.0 million, and -$8.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.